JP2010513387A - イオンチャネルモジュレーターとして有用な新規なケイ皮酸アミド誘導体 - Google Patents
イオンチャネルモジュレーターとして有用な新規なケイ皮酸アミド誘導体 Download PDFInfo
- Publication number
- JP2010513387A JP2010513387A JP2009542019A JP2009542019A JP2010513387A JP 2010513387 A JP2010513387 A JP 2010513387A JP 2009542019 A JP2009542019 A JP 2009542019A JP 2009542019 A JP2009542019 A JP 2009542019A JP 2010513387 A JP2010513387 A JP 2010513387A
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- chloro
- trifluoromethyl
- amino
- acrylamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- APEJMQOBVMLION-UHFFFAOYSA-N cinnamamide Chemical class NC(=O)C=CC1=CC=CC=C1 APEJMQOBVMLION-UHFFFAOYSA-N 0.000 title claims description 11
- 102000004310 Ion Channels Human genes 0.000 title abstract description 18
- APEJMQOBVMLION-VOTSOKGWSA-N trans-cinnamamide Chemical class NC(=O)\C=C\C1=CC=CC=C1 APEJMQOBVMLION-VOTSOKGWSA-N 0.000 claims abstract description 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 34
- 201000010099 disease Diseases 0.000 claims abstract description 17
- 208000035475 disorder Diseases 0.000 claims abstract description 16
- -1 methyl-sulfonyl-amino, phenyl-sulfonyl-amino, N-methyl-sulfonyl-carboxamide Chemical compound 0.000 claims description 88
- 229910052739 hydrogen Inorganic materials 0.000 claims description 69
- 239000001257 hydrogen Substances 0.000 claims description 69
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 55
- 239000000203 mixture Substances 0.000 claims description 53
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 42
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 39
- 125000003118 aryl group Chemical group 0.000 claims description 34
- 150000002431 hydrogen Chemical class 0.000 claims description 30
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 21
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 18
- 125000000850 2H-chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 14
- 208000002193 Pain Diseases 0.000 claims description 13
- 125000002837 carbocyclic group Chemical group 0.000 claims description 13
- 210000003038 endothelium Anatomy 0.000 claims description 13
- 230000002102 hyperpolarization Effects 0.000 claims description 13
- 230000001404 mediated effect Effects 0.000 claims description 13
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 13
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 13
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims description 12
- 102000004257 Potassium Channel Human genes 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 108020001213 potassium channel Proteins 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims description 10
- 125000001041 indolyl group Chemical group 0.000 claims description 10
- CNDIHLBEKKVGNA-UHFFFAOYSA-N n-(benzenesulfonyl)formamide Chemical compound O=CNS(=O)(=O)C1=CC=CC=C1 CNDIHLBEKKVGNA-UHFFFAOYSA-N 0.000 claims description 10
- HWJRQTQRAADPIC-UHFFFAOYSA-N n-cyanoformamide Chemical group O=CNC#N HWJRQTQRAADPIC-UHFFFAOYSA-N 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 10
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 230000004044 response Effects 0.000 claims description 9
- 206010010904 Convulsion Diseases 0.000 claims description 8
- 206010003119 arrhythmia Diseases 0.000 claims description 8
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims description 8
- 208000028017 Psychotic disease Diseases 0.000 claims description 7
- 206010015037 epilepsy Diseases 0.000 claims description 7
- QFBHCGFWZVVHSV-UHFFFAOYSA-N nitramidoperoxysulfonylformic acid Chemical compound [N+](=O)([O-])NOOS(=O)(=O)C(=O)O QFBHCGFWZVVHSV-UHFFFAOYSA-N 0.000 claims description 7
- CGZOSWPLTVPHKY-UXBLZVDNSA-N (e)-n-[5-chloro-2-(2h-tetrazol-5-yl)phenyl]-3-naphthalen-2-ylprop-2-enamide Chemical compound C=1C=C2C=CC=CC2=CC=1/C=C/C(=O)NC1=CC(Cl)=CC=C1C1=NN=NN1 CGZOSWPLTVPHKY-UXBLZVDNSA-N 0.000 claims description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 6
- 208000020925 Bipolar disease Diseases 0.000 claims description 6
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 6
- 206010049447 Tachyarrhythmia Diseases 0.000 claims description 6
- 208000001871 Tachycardia Diseases 0.000 claims description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 201000001881 impotence Diseases 0.000 claims description 6
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 5
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 claims description 5
- 125000002619 bicyclic group Chemical group 0.000 claims description 5
- 208000031225 myocardial ischemia Diseases 0.000 claims description 5
- 201000000980 schizophrenia Diseases 0.000 claims description 5
- LHELHSNLJXKBCT-DAFODLJHSA-N (e)-3-[3,5-bis(trifluoromethyl)phenyl]-n-(5-chloro-2-hydroxyphenyl)prop-2-enamide Chemical compound OC1=CC=C(Cl)C=C1NC(=O)\C=C\C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 LHELHSNLJXKBCT-DAFODLJHSA-N 0.000 claims description 4
- UMFVYBSAWGXCRC-DAFODLJHSA-N (e)-3-[3,5-bis(trifluoromethyl)phenyl]-n-[4-bromo-2-(2h-tetrazol-5-yl)phenyl]prop-2-enamide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(\C=C\C(=O)NC=2C(=CC(Br)=CC=2)C=2NN=NN=2)=C1 UMFVYBSAWGXCRC-DAFODLJHSA-N 0.000 claims description 4
- METVFLYABXYWRS-DAFODLJHSA-N (e)-3-[3,5-bis(trifluoromethyl)phenyl]-n-[4-iodo-2-(2h-tetrazol-5-yl)phenyl]prop-2-enamide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(\C=C\C(=O)NC=2C(=CC(I)=CC=2)C=2NN=NN=2)=C1 METVFLYABXYWRS-DAFODLJHSA-N 0.000 claims description 4
- OCUZIRLHOOTBNO-ZRDIBKRKSA-N (e)-3-naphthalen-2-yl-n-[2-(2h-tetrazol-5-yl)phenyl]prop-2-enamide Chemical compound C=1C=C2C=CC=CC2=CC=1/C=C/C(=O)NC1=CC=CC=C1C1=NN=NN1 OCUZIRLHOOTBNO-ZRDIBKRKSA-N 0.000 claims description 4
- GOHHTOVBDFWFQT-QPJJXVBHSA-N (e)-n-(5-chloro-2-hydroxyphenyl)-3-(3-nitrophenyl)prop-2-enamide Chemical compound OC1=CC=C(Cl)C=C1NC(=O)\C=C\C1=CC=CC([N+]([O-])=O)=C1 GOHHTOVBDFWFQT-QPJJXVBHSA-N 0.000 claims description 4
- TXTRITGPFAHELV-SOFGYWHQSA-N (e)-n-(5-chloro-4-fluoro-2-sulfamoylphenyl)-3-naphthalen-2-ylprop-2-enamide Chemical compound NS(=O)(=O)C1=CC(F)=C(Cl)C=C1NC(=O)\C=C\C1=CC=C(C=CC=C2)C2=C1 TXTRITGPFAHELV-SOFGYWHQSA-N 0.000 claims description 4
- NDZLDFGRKNEKOT-ZRDIBKRKSA-N (e)-n-[2-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-3-naphthalen-2-ylprop-2-enamide Chemical compound FC(F)(F)C(C(F)(F)F)(O)C1=CC=CC=C1NC(=O)\C=C\C1=CC=C(C=CC=C2)C2=C1 NDZLDFGRKNEKOT-ZRDIBKRKSA-N 0.000 claims description 4
- GGQHARTUXHZVNH-RVDMUPIBSA-N (e)-n-[2-(benzenesulfonamido)-5-chlorophenyl]-3-naphthalen-2-ylprop-2-enamide Chemical compound C=1C=C2C=CC=CC2=CC=1/C=C/C(=O)NC1=CC(Cl)=CC=C1NS(=O)(=O)C1=CC=CC=C1 GGQHARTUXHZVNH-RVDMUPIBSA-N 0.000 claims description 4
- YHCUGJVPCCXXOF-QPJJXVBHSA-N (e)-n-[4-bromo-2-(2h-tetrazol-5-yl)phenyl]-3-[3-(trifluoromethyl)phenyl]prop-2-enamide Chemical compound FC(F)(F)C1=CC=CC(\C=C\C(=O)NC=2C(=CC(Br)=CC=2)C=2NN=NN=2)=C1 YHCUGJVPCCXXOF-QPJJXVBHSA-N 0.000 claims description 4
- KRWFSTSSTRVBNH-UXBLZVDNSA-N (e)-n-[4-bromo-2-(2h-tetrazol-5-yl)phenyl]-3-naphthalen-2-ylprop-2-enamide Chemical compound C=1C(Br)=CC=C(NC(=O)\C=C\C=2C=C3C=CC=CC3=CC=2)C=1C1=NN=NN1 KRWFSTSSTRVBNH-UXBLZVDNSA-N 0.000 claims description 4
- GCPIOGNMWMOGDF-QHHAFSJGSA-N (e)-n-[5-chloro-2-(2h-tetrazol-5-yl)phenyl]-3-[4-fluoro-3-(trifluoromethyl)phenyl]prop-2-enamide Chemical compound C1=C(C(F)(F)F)C(F)=CC=C1\C=C\C(=O)NC1=CC(Cl)=CC=C1C1=NN=NN1 GCPIOGNMWMOGDF-QHHAFSJGSA-N 0.000 claims description 4
- RPMTVICURJNLOI-UXBLZVDNSA-N (e)-n-[5-chloro-2-(5-oxo-2h-1,2,4-oxadiazol-3-yl)phenyl]-3-naphthalen-2-ylprop-2-enamide Chemical compound C=1C=C2C=CC=CC2=CC=1/C=C/C(=O)NC1=CC(Cl)=CC=C1C1=NOC(=O)N1 RPMTVICURJNLOI-UXBLZVDNSA-N 0.000 claims description 4
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 4
- VKGKURAONZTKHE-SOFGYWHQSA-N 4,5-dichloro-2-[[(e)-3-naphthalen-2-ylprop-2-enoyl]amino]benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC(Cl)=C(Cl)C=C1NC(=O)\C=C\C1=CC=C(C=CC=C2)C2=C1 VKGKURAONZTKHE-SOFGYWHQSA-N 0.000 claims description 4
- NYQJPNKIXZIYMC-QHHAFSJGSA-N 4-chloro-2-[[(e)-3-(3,4-dichlorophenyl)prop-2-enoyl]amino]benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)\C=C\C1=CC=C(Cl)C(Cl)=C1 NYQJPNKIXZIYMC-QHHAFSJGSA-N 0.000 claims description 4
- YYLDFEJXZPESJV-MDWZMJQESA-N 4-chloro-2-[[(e)-3-(4-phenylphenyl)prop-2-enoyl]amino]benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1NC(=O)\C=C\C1=CC=C(C=2C=CC=CC=2)C=C1 YYLDFEJXZPESJV-MDWZMJQESA-N 0.000 claims description 4
- MCTLJAYSEVDVST-UXBLZVDNSA-N 4-chloro-2-[[(e)-3-naphthalen-2-ylprop-2-enoyl]amino]benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1NC(=O)\C=C\C1=CC=C(C=CC=C2)C2=C1 MCTLJAYSEVDVST-UXBLZVDNSA-N 0.000 claims description 4
- BWQMBZRZVQFRQA-UXBLZVDNSA-N 4-chloro-2-[[(e)-3-naphthalen-2-ylprop-2-enoyl]amino]benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)\C=C\C1=CC=C(C=CC=C2)C2=C1 BWQMBZRZVQFRQA-UXBLZVDNSA-N 0.000 claims description 4
- XUXXXFKCRITRJH-UXBLZVDNSA-N 4-chloro-n-cyano-2-[[(e)-3-naphthalen-2-ylprop-2-enoyl]amino]benzamide Chemical compound ClC1=CC=C(C(=O)NC#N)C(NC(=O)\C=C\C=2C=C3C=CC=CC3=CC=2)=C1 XUXXXFKCRITRJH-UXBLZVDNSA-N 0.000 claims description 4
- YKTHAFZGSUNUTG-UHFFFAOYSA-N 5-chloro-n-[4-(4-fluorophenyl)-2-(2h-tetrazol-5-yl)phenyl]-1h-indole-2-carboxamide Chemical compound C1=CC(F)=CC=C1C(C=C1C=2NN=NN=2)=CC=C1NC(=O)C1=CC2=CC(Cl)=CC=C2N1 YKTHAFZGSUNUTG-UHFFFAOYSA-N 0.000 claims description 4
- NAVPOCOMTPRCOC-UHFFFAOYSA-N 5-chloro-n-[5-chloro-2-(2h-tetrazol-5-yl)phenyl]-1h-indole-2-carboxamide Chemical compound C=1C2=CC(Cl)=CC=C2NC=1C(=O)NC1=CC(Cl)=CC=C1C1=NN=NN1 NAVPOCOMTPRCOC-UHFFFAOYSA-N 0.000 claims description 4
- LLGQLYYIIMJCTK-UHFFFAOYSA-N 6-bromo-n-[5-chloro-2-(2h-tetrazol-5-yl)phenyl]-2-oxochromene-3-carboxamide Chemical compound C=1C2=CC(Br)=CC=C2OC(=O)C=1C(=O)NC1=CC(Cl)=CC=C1C1=NN=NN1 LLGQLYYIIMJCTK-UHFFFAOYSA-N 0.000 claims description 4
- JWSLATHFQAEULD-UHFFFAOYSA-N 6-chloro-n-[5-chloro-2-(2h-tetrazol-5-yl)phenyl]-2h-chromene-3-carboxamide Chemical compound C=1C2=CC(Cl)=CC=C2OCC=1C(=O)NC1=CC(Cl)=CC=C1C1=NN=NN1 JWSLATHFQAEULD-UHFFFAOYSA-N 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 206010046543 Urinary incontinence Diseases 0.000 claims description 4
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 230000006793 arrhythmia Effects 0.000 claims description 4
- QGNBTYAQAPLTMX-UHFFFAOYSA-L calcium dobesilate Chemical group [Ca+2].OC1=CC=C(O)C(S([O-])(=O)=O)=C1.OC1=CC=C(O)C(S([O-])(=O)=O)=C1 QGNBTYAQAPLTMX-UHFFFAOYSA-L 0.000 claims description 4
- 229960005438 calcium dobesilate Drugs 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 230000001079 digestive effect Effects 0.000 claims description 4
- 206010013781 dry mouth Diseases 0.000 claims description 4
- 208000028867 ischemia Diseases 0.000 claims description 4
- NKVMKKHHWOXDKB-YRNVUSSQSA-N methyl 4-chloro-2-[[(e)-3-naphthalen-2-ylprop-2-enoyl]amino]benzenesulfonate Chemical compound COS(=O)(=O)C1=CC=C(Cl)C=C1NC(=O)\C=C\C1=CC=C(C=CC=C2)C2=C1 NKVMKKHHWOXDKB-YRNVUSSQSA-N 0.000 claims description 4
- RQKCBIWYUFAFCA-RVDMUPIBSA-N n-(benzenesulfonyl)-4-chloro-2-[[(e)-3-naphthalen-2-ylprop-2-enoyl]amino]benzamide Chemical compound C=1C=C2C=CC=CC2=CC=1/C=C/C(=O)NC1=CC(Cl)=CC=C1C(=O)NS(=O)(=O)C1=CC=CC=C1 RQKCBIWYUFAFCA-RVDMUPIBSA-N 0.000 claims description 4
- YTVOPQGTSREXFM-UHFFFAOYSA-N n-[4-bromo-2-(2h-tetrazol-5-yl)phenyl]-6-chloro-2h-chromene-3-carboxamide Chemical compound C=1C2=CC(Cl)=CC=C2OCC=1C(=O)NC1=CC=C(Br)C=C1C1=NN=NN1 YTVOPQGTSREXFM-UHFFFAOYSA-N 0.000 claims description 4
- 208000004296 neuralgia Diseases 0.000 claims description 4
- 229960003310 sildenafil Drugs 0.000 claims description 4
- 229960000835 tadalafil Drugs 0.000 claims description 4
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 claims description 4
- 229960002381 vardenafil Drugs 0.000 claims description 4
- 206010047302 ventricular tachycardia Diseases 0.000 claims description 4
- KJTPYXJGKLLESS-UNXLUWIOSA-N (e)-3-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(4-chlorophenyl)-2-(2h-tetrazol-5-yl)phenyl]prop-2-enamide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(\C=C\C(=O)NC=2C(=CC(=CC=2)C=2C=CC(Cl)=CC=2)C2=NNN=N2)=C1 KJTPYXJGKLLESS-UNXLUWIOSA-N 0.000 claims description 3
- XYQDIFBKCINHCF-YRNVUSSQSA-N (e)-n-(2-acetamido-5-chlorophenyl)-3-naphthalen-2-ylprop-2-enamide Chemical compound CC(=O)NC1=CC=C(Cl)C=C1NC(=O)\C=C\C1=CC=C(C=CC=C2)C2=C1 XYQDIFBKCINHCF-YRNVUSSQSA-N 0.000 claims description 3
- GKLWGEQHPOUYIW-UXBLZVDNSA-N (e)-n-(2-amino-5-chlorophenyl)-3-naphthalen-2-ylprop-2-enamide Chemical compound NC1=CC=C(Cl)C=C1NC(=O)\C=C\C1=CC=C(C=CC=C2)C2=C1 GKLWGEQHPOUYIW-UXBLZVDNSA-N 0.000 claims description 3
- RNIYQJCUEVEEOS-UXBLZVDNSA-N (e)-n-(5-chloro-2-nitrophenyl)-3-naphthalen-2-ylprop-2-enamide Chemical compound [O-][N+](=O)C1=CC=C(Cl)C=C1NC(=O)\C=C\C1=CC=C(C=CC=C2)C2=C1 RNIYQJCUEVEEOS-UXBLZVDNSA-N 0.000 claims description 3
- YSBXUYYPPGONLP-YRNVUSSQSA-N (e)-n-[5-chloro-2-(methanesulfonamido)phenyl]-3-naphthalen-2-ylprop-2-enamide Chemical compound CS(=O)(=O)NC1=CC=C(Cl)C=C1NC(=O)\C=C\C1=CC=C(C=CC=C2)C2=C1 YSBXUYYPPGONLP-YRNVUSSQSA-N 0.000 claims description 3
- SFNWSPBFQRRTFZ-UXBLZVDNSA-N (e)-n-[5-chloro-2-(trifluoromethylsulfonylamino)phenyl]-3-naphthalen-2-ylprop-2-enamide Chemical compound FC(F)(F)S(=O)(=O)NC1=CC=C(Cl)C=C1NC(=O)\C=C\C1=CC=C(C=CC=C2)C2=C1 SFNWSPBFQRRTFZ-UXBLZVDNSA-N 0.000 claims description 3
- LKBLPSKMSDFDBS-UXBLZVDNSA-N (e)-n-[5-chloro-2-[(2,2,2-trifluoroacetyl)amino]phenyl]-3-naphthalen-2-ylprop-2-enamide Chemical compound FC(F)(F)C(=O)NC1=CC=C(Cl)C=C1NC(=O)\C=C\C1=CC=C(C=CC=C2)C2=C1 LKBLPSKMSDFDBS-UXBLZVDNSA-N 0.000 claims description 3
- VRHIQTXQOPZMJT-YRNVUSSQSA-N 4-chloro-n-methylsulfonyl-2-[[(e)-3-naphthalen-2-ylprop-2-enoyl]amino]benzamide Chemical compound CS(=O)(=O)NC(=O)C1=CC=C(Cl)C=C1NC(=O)\C=C\C1=CC=C(C=CC=C2)C2=C1 VRHIQTXQOPZMJT-YRNVUSSQSA-N 0.000 claims description 3
- 206010003130 Arrhythmia supraventricular Diseases 0.000 claims description 3
- 206010048994 Bladder spasm Diseases 0.000 claims description 3
- 206010049765 Bradyarrhythmia Diseases 0.000 claims description 3
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 3
- 208000006029 Cardiomegaly Diseases 0.000 claims description 3
- 208000010412 Glaucoma Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 206010065390 Inflammatory pain Diseases 0.000 claims description 3
- 208000026139 Memory disease Diseases 0.000 claims description 3
- 208000019695 Migraine disease Diseases 0.000 claims description 3
- 206010030043 Ocular hypertension Diseases 0.000 claims description 3
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims description 3
- 230000002159 abnormal effect Effects 0.000 claims description 3
- 230000001746 atrial effect Effects 0.000 claims description 3
- 208000006218 bradycardia Diseases 0.000 claims description 3
- 208000029078 coronary artery disease Diseases 0.000 claims description 3
- 230000006735 deficit Effects 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 206010027599 migraine Diseases 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 208000021722 neuropathic pain Diseases 0.000 claims description 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 3
- 208000023504 respiratory system disease Diseases 0.000 claims description 3
- 230000033764 rhythmic process Effects 0.000 claims description 3
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 3
- 208000003663 ventricular fibrillation Diseases 0.000 claims description 3
- MSKGZYOWCMVRKC-QHHAFSJGSA-N (e)-n-[5-chloro-2-(2h-tetrazol-5-yl)phenyl]-3-(3,4-dichlorophenyl)prop-2-enamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1/C=C/C(=O)NC1=CC(Cl)=CC=C1C1=NN=NN1 MSKGZYOWCMVRKC-QHHAFSJGSA-N 0.000 claims description 2
- AZHSJTNBTLJFMA-UXBLZVDNSA-N (e)-n-[5-chloro-2-(2h-tetrazol-5-ylmethoxy)phenyl]-3-naphthalen-2-ylprop-2-enamide Chemical compound C=1C=C2C=CC=CC2=CC=1/C=C/C(=O)NC1=CC(Cl)=CC=C1OCC1=NN=NN1 AZHSJTNBTLJFMA-UXBLZVDNSA-N 0.000 claims description 2
- 206010001497 Agitation Diseases 0.000 claims description 2
- 201000004384 Alopecia Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000000044 Amnesia Diseases 0.000 claims description 2
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 206010003225 Arteriospasm coronary Diseases 0.000 claims description 2
- 206010003591 Ataxia Diseases 0.000 claims description 2
- 206010003805 Autism Diseases 0.000 claims description 2
- 208000020706 Autistic disease Diseases 0.000 claims description 2
- 201000006474 Brain Ischemia Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
- 206010010774 Constipation Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010011878 Deafness Diseases 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- 208000005171 Dysmenorrhea Diseases 0.000 claims description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 claims description 2
- 206010057671 Female sexual dysfunction Diseases 0.000 claims description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 2
- 206010062016 Immunosuppression Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 206010022562 Intermittent claudication Diseases 0.000 claims description 2
- 206010057672 Male sexual dysfunction Diseases 0.000 claims description 2
- 208000019022 Mood disease Diseases 0.000 claims description 2
- 208000026072 Motor neurone disease Diseases 0.000 claims description 2
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 2
- 206010034759 Petit mal epilepsy Diseases 0.000 claims description 2
- 208000005107 Premature Birth Diseases 0.000 claims description 2
- 206010036590 Premature baby Diseases 0.000 claims description 2
- 208000003782 Raynaud disease Diseases 0.000 claims description 2
- 208000012322 Raynaud phenomenon Diseases 0.000 claims description 2
- 208000036071 Rhinorrhea Diseases 0.000 claims description 2
- 206010039101 Rhinorrhoea Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 206010047163 Vasospasm Diseases 0.000 claims description 2
- 206010065341 Ventricular tachyarrhythmia Diseases 0.000 claims description 2
- 208000028311 absence seizure Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 208000028683 bipolar I disease Diseases 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 230000000112 colonic effect Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 208000028329 epileptic seizure Diseases 0.000 claims description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 2
- 230000007160 gastrointestinal dysfunction Effects 0.000 claims description 2
- 230000003676 hair loss Effects 0.000 claims description 2
- 230000010370 hearing loss Effects 0.000 claims description 2
- 231100000888 hearing loss Toxicity 0.000 claims description 2
- 208000016354 hearing loss disease Diseases 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 2
- 201000008980 hyperinsulinism Diseases 0.000 claims description 2
- 230000001506 immunosuppresive effect Effects 0.000 claims description 2
- 208000021156 intermittent vascular claudication Diseases 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 230000006984 memory degeneration Effects 0.000 claims description 2
- 208000023060 memory loss Diseases 0.000 claims description 2
- 208000005264 motor neuron disease Diseases 0.000 claims description 2
- 201000006938 muscular dystrophy Diseases 0.000 claims description 2
- 230000003274 myotonic effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 201000002859 sleep apnea Diseases 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 208000020685 sleep-wake disease Diseases 0.000 claims description 2
- 230000009529 traumatic brain injury Effects 0.000 claims description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 230000004393 visual impairment Effects 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 13
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 229930016911 cinnamic acid Natural products 0.000 claims 2
- 235000013985 cinnamic acid Nutrition 0.000 claims 2
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims 2
- 206010071445 Bladder outlet obstruction Diseases 0.000 claims 1
- 208000003890 Coronary Vasospasm Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 206010054048 Postoperative ileus Diseases 0.000 claims 1
- 208000003800 Urinary Bladder Neck Obstruction Diseases 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 201000011634 coronary artery vasospasm Diseases 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 230000033228 biological regulation Effects 0.000 abstract description 3
- 230000003389 potentiating effect Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 69
- 125000005843 halogen group Chemical group 0.000 description 61
- 150000001875 compounds Chemical class 0.000 description 56
- 239000007787 solid Substances 0.000 description 53
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 44
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 32
- 125000001309 chloro group Chemical group Cl* 0.000 description 30
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
- 239000000725 suspension Substances 0.000 description 25
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 24
- 238000003756 stirring Methods 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 19
- 238000002425 crystallisation Methods 0.000 description 19
- 230000008025 crystallization Effects 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 239000011541 reaction mixture Substances 0.000 description 17
- 238000003818 flash chromatography Methods 0.000 description 16
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 16
- 108090000862 Ion Channels Proteins 0.000 description 15
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 239000003480 eluent Substances 0.000 description 13
- 125000001153 fluoro group Chemical group F* 0.000 description 13
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 12
- 235000019341 magnesium sulphate Nutrition 0.000 description 12
- 239000008186 active pharmaceutical agent Substances 0.000 description 10
- 125000001246 bromo group Chemical group Br* 0.000 description 10
- 239000013058 crude material Substances 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 239000000741 silica gel Substances 0.000 description 9
- 229910002027 silica gel Inorganic materials 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 8
- 102000016469 Large-Conductance Calcium-Activated Potassium Channels Human genes 0.000 description 8
- 108010092555 Large-Conductance Calcium-Activated Potassium Channels Proteins 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
- 239000012267 brine Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 125000001624 naphthyl group Chemical group 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 6
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 5
- 102000011045 Chloride Channels Human genes 0.000 description 5
- 108010062745 Chloride Channels Proteins 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- CGPVQTAJEFJLPO-UHFFFAOYSA-N 1,1-bis(methylsulfonyl)urea Chemical compound CS(=O)(=O)N(C(N)=O)S(C)(=O)=O CGPVQTAJEFJLPO-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 3
- WZLOLBBALZMMHJ-OWOJBTEDSA-N (e)-3-[3,5-bis(trifluoromethyl)phenyl]prop-2-enoyl chloride Chemical compound FC(F)(F)C1=CC(\C=C\C(Cl)=O)=CC(C(F)(F)F)=C1 WZLOLBBALZMMHJ-OWOJBTEDSA-N 0.000 description 3
- KWGPBDBAAXYWOJ-SOFGYWHQSA-N (e)-3-naphthalen-2-ylprop-2-enoic acid Chemical compound C1=CC=CC2=CC(/C=C/C(=O)O)=CC=C21 KWGPBDBAAXYWOJ-SOFGYWHQSA-N 0.000 description 3
- SWFNPENEBHAHEB-UHFFFAOYSA-N 2-amino-4-chlorophenol Chemical compound NC1=CC(Cl)=CC=C1O SWFNPENEBHAHEB-UHFFFAOYSA-N 0.000 description 3
- CATSHJCKVONEFX-UHFFFAOYSA-N 4-bromo-2-(2h-tetrazol-5-yl)aniline Chemical compound NC1=CC=C(Br)C=C1C1=NN=NN1 CATSHJCKVONEFX-UHFFFAOYSA-N 0.000 description 3
- KKTZHFZXGZLTLZ-UHFFFAOYSA-N 5-chloro-2-(2h-tetrazol-5-yl)aniline Chemical compound NC1=CC(Cl)=CC=C1C1=NNN=N1 KKTZHFZXGZLTLZ-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 208000002780 macular degeneration Diseases 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000036390 resting membrane potential Effects 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000012258 stirred mixture Substances 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 2
- RRLUFPHCTSFKNR-DUXPYHPUSA-N (e)-3-(3,4-dichlorophenyl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=C(Cl)C(Cl)=C1 RRLUFPHCTSFKNR-DUXPYHPUSA-N 0.000 description 2
- PAYFEYFJDXGKLA-UHFFFAOYSA-N 1,1-bis(benzenesulfonyl)urea Chemical compound C=1C=CC=CC=1S(=O)(=O)N(C(=O)N)S(=O)(=O)C1=CC=CC=C1 PAYFEYFJDXGKLA-UHFFFAOYSA-N 0.000 description 2
- OMQCGHBXGJBBOL-UHFFFAOYSA-N 2-amino-4-chlorobenzenesulfonic acid Chemical compound NC1=CC(Cl)=CC=C1S(O)(=O)=O OMQCGHBXGJBBOL-UHFFFAOYSA-N 0.000 description 2
- JYYLQSCZISREGY-UHFFFAOYSA-N 2-amino-4-chlorobenzoic acid Chemical compound NC1=CC(Cl)=CC=C1C(O)=O JYYLQSCZISREGY-UHFFFAOYSA-N 0.000 description 2
- HTATYXFLUOFSIH-UHFFFAOYSA-N 2-amino-5-(4-chlorophenyl)benzonitrile Chemical compound C1=C(C#N)C(N)=CC=C1C1=CC=C(Cl)C=C1 HTATYXFLUOFSIH-UHFFFAOYSA-N 0.000 description 2
- OYZHFMJOKUVVKM-UHFFFAOYSA-N 2-amino-n-(benzenesulfonyl)-4-chlorobenzamide Chemical compound NC1=CC(Cl)=CC=C1C(=O)NS(=O)(=O)C1=CC=CC=C1 OYZHFMJOKUVVKM-UHFFFAOYSA-N 0.000 description 2
- JAHIPDTWWVYVRV-UHFFFAOYSA-N 4-chloro-2-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1[N+]([O-])=O JAHIPDTWWVYVRV-UHFFFAOYSA-N 0.000 description 2
- FUQOTYRCMBZFOL-UHFFFAOYSA-N 5-chloro-1H-indole-2-carboxylic acid Chemical compound ClC1=CC=C2NC(C(=O)O)=CC2=C1 FUQOTYRCMBZFOL-UHFFFAOYSA-N 0.000 description 2
- LBBTVMUXRHWFQA-UHFFFAOYSA-N 5-chloro-1h-indole-2-carbonyl chloride Chemical compound ClC1=CC=C2NC(C(=O)Cl)=CC2=C1 LBBTVMUXRHWFQA-UHFFFAOYSA-N 0.000 description 2
- LOWRVANIUBCXCU-UHFFFAOYSA-N 5-chloro-2h-chromene-3-carboxylic acid Chemical compound C1=CC=C2OCC(C(=O)O)=CC2=C1Cl LOWRVANIUBCXCU-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- YDVJBLJCSLVMSY-UHFFFAOYSA-N carbamoyl cyanide Chemical group NC(=O)C#N YDVJBLJCSLVMSY-UHFFFAOYSA-N 0.000 description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 201000005682 chronic closed-angle glaucoma Diseases 0.000 description 2
- 229940126208 compound 22 Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000011190 diabetic macular edema Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000003372 electrophysiological method Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 125000002346 iodo group Chemical group I* 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000028161 membrane depolarization Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- DIORMHZUUKOISG-UHFFFAOYSA-N sulfoformic acid Chemical compound OC(=O)S(O)(=O)=O DIORMHZUUKOISG-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- CAYQIZIAYYNFCS-UHFFFAOYSA-N (4-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1 CAYQIZIAYYNFCS-UHFFFAOYSA-N 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- SQOOOIAYRCYPSW-DUXPYHPUSA-N (e)-3-(3,4-dichlorophenyl)prop-2-enoyl chloride Chemical compound ClC(=O)\C=C\C1=CC=C(Cl)C(Cl)=C1 SQOOOIAYRCYPSW-DUXPYHPUSA-N 0.000 description 1
- DMJDEZUEYXVYNO-DHZHZOJOSA-N (e)-3-(4-phenylphenyl)prop-2-enoic acid Chemical compound C1=CC(/C=C/C(=O)O)=CC=C1C1=CC=CC=C1 DMJDEZUEYXVYNO-DHZHZOJOSA-N 0.000 description 1
- IZKCKOPHMWHBHR-OWOJBTEDSA-N (e)-3-[3,5-bis(trifluoromethyl)phenyl]prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 IZKCKOPHMWHBHR-OWOJBTEDSA-N 0.000 description 1
- HGQSKTQYEWJJRZ-SNAWJCMRSA-N (e)-3-[3-(trifluoromethyl)phenyl]prop-2-enoyl chloride Chemical compound FC(F)(F)C1=CC=CC(\C=C\C(Cl)=O)=C1 HGQSKTQYEWJJRZ-SNAWJCMRSA-N 0.000 description 1
- DESJUJUEXMNIGB-DUXPYHPUSA-N (e)-3-[4-fluoro-3-(trifluoromethyl)phenyl]prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=C(F)C(C(F)(F)F)=C1 DESJUJUEXMNIGB-DUXPYHPUSA-N 0.000 description 1
- IPKQVFIYJDYABU-SOFGYWHQSA-N (e)-3-naphthalen-2-ylprop-2-enoyl chloride Chemical compound C1=CC=CC2=CC(/C=C/C(=O)Cl)=CC=C21 IPKQVFIYJDYABU-SOFGYWHQSA-N 0.000 description 1
- OMUIRXFBBKGWKH-UXBLZVDNSA-N (e)-n-(5-chloro-2-hydroxyphenyl)-3-naphthalen-2-ylprop-2-enamide Chemical compound OC1=CC=C(Cl)C=C1NC(=O)\C=C\C1=CC=C(C=CC=C2)C2=C1 OMUIRXFBBKGWKH-UXBLZVDNSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- IKQCSJBQLWJEPU-UHFFFAOYSA-N 2,5-dihydroxybenzenesulfonic acid Chemical class OC1=CC=C(O)C(S(O)(=O)=O)=C1 IKQCSJBQLWJEPU-UHFFFAOYSA-N 0.000 description 1
- HSCFLKMJUGBEEQ-UHFFFAOYSA-N 2-(2-aminophenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound NC1=CC=CC=C1C(O)(C(F)(F)F)C(F)(F)F HSCFLKMJUGBEEQ-UHFFFAOYSA-N 0.000 description 1
- GUCGQKSPWMDAEX-UHFFFAOYSA-N 2-(2h-tetrazol-5-yl)aniline Chemical compound NC1=CC=CC=C1C1=NNN=N1 GUCGQKSPWMDAEX-UHFFFAOYSA-N 0.000 description 1
- FTXLOOQNXOKIFU-UHFFFAOYSA-N 2-amino-4-chloro-n-methylsulfonylbenzamide Chemical compound CS(=O)(=O)NC(=O)C1=CC=C(Cl)C=C1N FTXLOOQNXOKIFU-UHFFFAOYSA-N 0.000 description 1
- OATYCBHROMXWJO-UHFFFAOYSA-N 2-amino-5-bromobenzonitrile Chemical compound NC1=CC=C(Br)C=C1C#N OATYCBHROMXWJO-UHFFFAOYSA-N 0.000 description 1
- AKLDPNVZTZIVFA-UHFFFAOYSA-N 2-azaniumyl-4,5-dichlorobenzenesulfonate Chemical compound NC1=CC(Cl)=C(Cl)C=C1S(O)(=O)=O AKLDPNVZTZIVFA-UHFFFAOYSA-N 0.000 description 1
- YAYZQLYBTWWZTG-UHFFFAOYSA-N 2-chloro-5-fluorobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC(F)=CC=C1Cl YAYZQLYBTWWZTG-UHFFFAOYSA-N 0.000 description 1
- IGAVHJWKCUOTBA-UHFFFAOYSA-N 3-(2-amino-4-chlorophenyl)-2h-1,2,4-oxadiazol-5-one Chemical compound NC1=CC(Cl)=CC=C1C1=NOC(=O)N1 IGAVHJWKCUOTBA-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- WZLOLBBALZMMHJ-UHFFFAOYSA-N 3-[3,5-bis(trifluoromethyl)phenyl]prop-2-enoyl chloride Chemical compound FC(F)(F)C1=CC(C=CC(Cl)=O)=CC(C(F)(F)F)=C1 WZLOLBBALZMMHJ-UHFFFAOYSA-N 0.000 description 1
- BLAIKKALLYIUAS-UHFFFAOYSA-N 3-[4-fluoro-3-(trifluoromethyl)phenyl]prop-2-enoyl chloride Chemical compound FC1=CC=C(C=CC(Cl)=O)C=C1C(F)(F)F BLAIKKALLYIUAS-UHFFFAOYSA-N 0.000 description 1
- OKHTXMYUDWHGOC-UHFFFAOYSA-N 4-(3-chlorophenyl)butan-2-one Chemical compound CC(=O)CCC1=CC=CC(Cl)=C1 OKHTXMYUDWHGOC-UHFFFAOYSA-N 0.000 description 1
- UQYUDTURYUISOH-UHFFFAOYSA-N 4-(4-chlorophenyl)-2-(2h-tetrazol-5-yl)aniline Chemical compound NC1=CC=C(C=2C=CC(Cl)=CC=2)C=C1C1=NN=NN1 UQYUDTURYUISOH-UHFFFAOYSA-N 0.000 description 1
- DJDSXOYKNOCYOW-UHFFFAOYSA-N 4-(4-fluorophenyl)-2-(2h-tetrazol-5-yl)aniline Chemical compound NC1=CC=C(C=2C=CC(F)=CC=2)C=C1C1=NN=NN1 DJDSXOYKNOCYOW-UHFFFAOYSA-N 0.000 description 1
- VOUOEEPUGRWSQO-UHFFFAOYSA-N 4-chloro-n-methylsulfonyl-2-nitrobenzamide Chemical compound CS(=O)(=O)NC(=O)C1=CC=C(Cl)C=C1[N+]([O-])=O VOUOEEPUGRWSQO-UHFFFAOYSA-N 0.000 description 1
- OVMLAJYFEMWMAW-UHFFFAOYSA-N 4-iodo-2-(2h-tetrazol-5-yl)aniline Chemical compound NC1=CC=C(I)C=C1C1=NN=NN1 OVMLAJYFEMWMAW-UHFFFAOYSA-N 0.000 description 1
- ZCWXYZBQDNFULS-UHFFFAOYSA-N 5-chloro-2-nitroaniline Chemical compound NC1=CC(Cl)=CC=C1[N+]([O-])=O ZCWXYZBQDNFULS-UHFFFAOYSA-N 0.000 description 1
- LHZWVEWBXKXFMS-UHFFFAOYSA-N 6-bromo-2-oxochromene-3-carbonyl chloride Chemical compound BrC1=CC=C2OC(=O)C(C(=O)Cl)=CC2=C1 LHZWVEWBXKXFMS-UHFFFAOYSA-N 0.000 description 1
- XFQHPAXNKDYMOX-UHFFFAOYSA-N 6-bromo-2-oxochromene-3-carboxylic acid Chemical compound BrC1=CC=C2OC(=O)C(C(=O)O)=CC2=C1 XFQHPAXNKDYMOX-UHFFFAOYSA-N 0.000 description 1
- HGFGWTNRUGRBNQ-UHFFFAOYSA-N 6-chloro-2h-chromene-3-carbonyl chloride Chemical compound ClC1=CC=C2OCC(C(=O)Cl)=CC2=C1 HGFGWTNRUGRBNQ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- SBNHWBPBPYLXJD-UHFFFAOYSA-N C1=CC=C(C(=C1)C2=NNN=N2)NBr Chemical compound C1=CC=C(C(=C1)C2=NNN=N2)NBr SBNHWBPBPYLXJD-UHFFFAOYSA-N 0.000 description 1
- SWXRKAIKWJKCJP-UHFFFAOYSA-N C1=CC=C(C(=C1)C2=NNN=N2)NCl Chemical compound C1=CC=C(C(=C1)C2=NNN=N2)NCl SWXRKAIKWJKCJP-UHFFFAOYSA-N 0.000 description 1
- 102000005702 Calcium-Activated Potassium Channels Human genes 0.000 description 1
- 108010045489 Calcium-Activated Potassium Channels Proteins 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- RENMDAKOXSCIGH-UHFFFAOYSA-N Chloroacetonitrile Chemical compound ClCC#N RENMDAKOXSCIGH-UHFFFAOYSA-N 0.000 description 1
- 206010052129 Ciliary hyperaemia Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 206010055665 Corneal neovascularisation Diseases 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- 208000026292 Cystic Kidney disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000020358 Learning disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 229940127315 Potassium Channel Openers Drugs 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 201000007527 Retinal artery occlusion Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000026723 Urinary tract disease Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WGJVYWVEWCTCHX-UHFFFAOYSA-N benzyl 2-(tert-butylamino)acetate Chemical compound CC(C)(C)NCC(=O)OCC1=CC=CC=C1 WGJVYWVEWCTCHX-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000003857 carboxamides Chemical group 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 201000000159 corneal neovascularization Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- UKPGCPIEUXKREW-UHFFFAOYSA-N dichloromethane;n,n-dimethylacetamide Chemical compound ClCCl.CN(C)C(C)=O UKPGCPIEUXKREW-UHFFFAOYSA-N 0.000 description 1
- 125000001891 dimethoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- OIRDBPQYVWXNSJ-UHFFFAOYSA-N methyl trifluoromethansulfonate Chemical compound COS(=O)(=O)C(F)(F)F OIRDBPQYVWXNSJ-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 201000003142 neovascular glaucoma Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000008587 neuronal excitability Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 230000001777 nootropic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000000010 osteolytic effect Effects 0.000 description 1
- CCVKPWUMYBYHCD-UHFFFAOYSA-N oxolane;pyridine Chemical compound C1CCOC1.C1=CC=NC=C1 CCVKPWUMYBYHCD-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- IPOVLZSJBYKHHU-UHFFFAOYSA-N piperidin-3-ylmethanamine Chemical compound NCC1CCCNC1 IPOVLZSJBYKHHU-UHFFFAOYSA-N 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000029219 regulation of pH Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000004644 retinal vein occlusion Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 201000009881 secretory diarrhea Diseases 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940075554 sorbate Drugs 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- GRGCWBWNLSTIEN-UHFFFAOYSA-N trifluoromethanesulfonyl chloride Chemical compound FC(F)(F)S(Cl)(=O)=O GRGCWBWNLSTIEN-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
- C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
- C07C309/15—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton the nitrogen atom of at least one of the amino groups being part of any of the groups, X being a hetero atom, Y being any atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C1/00—Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon
- C07C1/26—Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon starting from organic compounds containing only halogen atoms as hetero-atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C17/00—Preparation of halogenated hydrocarbons
- C07C17/093—Preparation of halogenated hydrocarbons by replacement by halogens
- C07C17/10—Preparation of halogenated hydrocarbons by replacement by halogens of hydrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/09—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by at least two halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/51—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2529/00—Catalysts comprising molecular sieves
- C07C2529/04—Catalysts comprising molecular sieves having base-exchange properties, e.g. crystalline zeolites, pillared clays
- C07C2529/06—Crystalline aluminosilicate zeolites; Isomorphous compounds thereof
- C07C2529/40—Crystalline aluminosilicate zeolites; Isomorphous compounds thereof of the pentasil type, e.g. types ZSM-5, ZSM-8 or ZSM-11
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Gynecology & Obstetrics (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200601657 | 2006-12-18 | ||
| US87078106P | 2006-12-19 | 2006-12-19 | |
| DKPA200700481 | 2007-03-28 | ||
| PCT/EP2007/064015 WO2008074755A2 (en) | 2006-12-18 | 2007-12-17 | Novel cinnamic amide derivatives useful as ion channel modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010513387A true JP2010513387A (ja) | 2010-04-30 |
| JP2010513387A5 JP2010513387A5 (cg-RX-API-DMAC7.html) | 2011-02-10 |
Family
ID=39300490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009542019A Abandoned JP2010513387A (ja) | 2006-12-18 | 2007-12-17 | イオンチャネルモジュレーターとして有用な新規なケイ皮酸アミド誘導体 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20100087496A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2121569A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2010513387A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008074755A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9198886B2 (en) * | 2006-08-16 | 2015-12-01 | Pedro Cuevas Sánchez | Use of 2,5-dihydroxybenzene for the treatment of ocular diseases |
| CN102643207A (zh) * | 2011-02-21 | 2012-08-22 | 南京农业大学 | 3-(2-萘基)丙烯酰胺类衍生物及其制备方法与用途 |
| CN102258508A (zh) * | 2011-04-14 | 2011-11-30 | 威海迪素制药有限公司 | 芳基丙烯酸衍生物抗癫痫的用途 |
| CN117045648A (zh) * | 2023-09-07 | 2023-11-14 | 复旦大学 | Bk通道开放剂在用于治疗骨质疏松症中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3158610A (en) * | 1964-01-03 | 1964-11-24 | American Cyanamid Co | 2-styrylbenzoxazole brighteners |
| DE1670908A1 (de) * | 1967-08-16 | 1971-04-29 | Hoechst Ag | Neue Benzimidazolverbindungen,Verfahren zu ihrer Herstellung und ihre Verwendung als optische Aufhellungsmittel |
| US6127392A (en) * | 1997-08-05 | 2000-10-03 | American Home Products Corporation | Anthranilic acid analogs |
| US6046239A (en) * | 1997-08-05 | 2000-04-04 | American Home Products Corporation | Anthranilic acid analogs |
| AR034897A1 (es) * | 2001-08-07 | 2004-03-24 | Hoffmann La Roche | Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos |
| JP3835749B2 (ja) * | 2002-04-15 | 2006-10-18 | 日本曹達株式会社 | フェノール性化合物を用いた記録材料 |
| WO2003091213A1 (en) * | 2002-04-25 | 2003-11-06 | Yamanouchi Pharmaceutical Co., Ltd. | Novel amide derivatives or salts thereof |
| AU2003258491A1 (en) * | 2002-09-05 | 2004-03-29 | Neurosearch A/S | Amide derivatives and their use as chloride channel blockers |
-
2007
- 2007-12-17 US US12/519,683 patent/US20100087496A1/en not_active Abandoned
- 2007-12-17 EP EP07857649A patent/EP2121569A2/en not_active Withdrawn
- 2007-12-17 JP JP2009542019A patent/JP2010513387A/ja not_active Abandoned
- 2007-12-17 WO PCT/EP2007/064015 patent/WO2008074755A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20100087496A1 (en) | 2010-04-08 |
| EP2121569A2 (en) | 2009-11-25 |
| WO2008074755A3 (en) | 2008-10-02 |
| WO2008074755A2 (en) | 2008-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5501369B2 (ja) | 可溶性グアニレートシクラーゼ活性化剤 | |
| ES2398606T3 (es) | Derivados de 2-piridin-carboxamida como moduladores de los canales de sodio | |
| JP4426660B2 (ja) | ピラゾール誘導体、その製法および医薬としてのその使用 | |
| AU2006216917A1 (en) | Benzazole potentiators of metabotropic glutamate receptors | |
| JP6491679B2 (ja) | Gabaa受容体活性のモジュレーターとしてのイミダゾピリダジン誘導体 | |
| MX2013008111A (es) | Derivados de oxazina y su uso en el tratamiento de transtornos neurologicos. | |
| JP2012509877A5 (cg-RX-API-DMAC7.html) | ||
| EP2411001A1 (en) | P2x3, receptor antagonists for treatment of pain | |
| CN101970405A (zh) | 吲哚及其治疗用途 | |
| JP2014521749A (ja) | ヘテロアリールナトリウムチャネル阻害剤 | |
| AU2005299797A1 (en) | Heterocyclic indanone potentiators of metabotropic glutamate receptors | |
| JP6250674B2 (ja) | N型カルシウムチャネル遮断剤としてのピロロピラゾール | |
| TWI582080B (zh) | 礦皮質素受體拮抗劑 | |
| JP2010513387A (ja) | イオンチャネルモジュレーターとして有用な新規なケイ皮酸アミド誘導体 | |
| WO2009068557A1 (en) | Novel phenyl-acetamide and phenyl-propionamide derivatives useful as potassium channel modulators | |
| EP2152679A1 (en) | Benzisoxazole derivatives as potassium channel modulators for the treatment of e.g. respiratory diseases, epilepsy and convulsions | |
| AU2015247575C1 (en) | Polycyclic hERG activators | |
| JP2010526850A (ja) | カリウムチャネル調節剤として有用な、新規な芳香族複素環式カルボン酸アミド誘導体 | |
| JP2010526038A (ja) | イオンチャネル調節剤として有用なβ−ケト−アミド誘導体 | |
| CN105228609A (zh) | 新的转录因子调节剂 | |
| US20100137381A1 (en) | Acetamide derivatives as potassium channel modulators | |
| US20100144809A1 (en) | Novel benzamidine derivatives useful as potassium channel modulators | |
| JP2022163241A (ja) | P2x4受容体拮抗剤 | |
| TW200800187A (en) | New indole-containing beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | |
| EP2121640A1 (en) | Novel semicarbazide and carbonylhydrazide derivatives useful as potassium channel modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101215 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101215 |
|
| A762 | Written abandonment of application |
Free format text: JAPANESE INTERMEDIATE CODE: A762 Effective date: 20110308 |